Clinical trials
Lung cancer clinical trials
Cancer that begins in the lungs, often linked to smoking but also affecting non-smokers. We’re tracking 2,010 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT00682032Recruiting
Beta-glucan for non-small cell lung cancer
This study tests whether beta-glucan, a supplement taken by mouth, can help people with non-small cell lung cancer. You may be able to join if you’re newly diagnosed (no recent treatment) and can safely take pills.
Louisville, KentuckyAges 18 years+ - NCT07489391Recruiting
Exercise during radiation for lung cancer
This trial tests whether adding a structured exercise program during radiation and chemotherapy helps people with locally advanced lung cancer. It aims to improve physical function and quality of life.
Barcelona, CataloniaAges 18 years+ - NCT07488507Recruiting
Combined biopsy for lung cancer spread in the chest
This trial tests a new way to take tissue samples from suspicious spots in the chest (mediastinum) in people with lung cancer. It aims to see if combining two biopsy methods is safer and more accurate than one alone.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT07480213RecruitingPhase 1/Phase 2
CAR-NK cell therapy for relapsed small cell lung cancer
This trial tests a new type of immunotherapy called dual-target CAR-NK cells for people with small cell lung cancer that has returned or not responded to treatment. The treatment uses your own immune cells, modified in a lab, to better recognize and attack cancer cells.
Shenzhen, GuangdongAges 18–75 - NCT07477158Recruiting
Comparing two lung cancer surgeries for recovery and quality of life
This study compares two types of lung cancer surgery—removing just the tumor section (segmentectomy) or the whole lobe (lobectomy)—done through small cuts (minimally invasive). The goal is to see which approach leads to better daily living and recovery for early-stage lung cancer patients.
Madrid, MadridAges 18 years+ - NCT07465757RecruitingPhase 2
Study of alisertib and paclitaxel for small cell lung cancer
This trial tests a combination of two drugs, alisertib and paclitaxel, for people with small cell lung cancer (SCLC) who have already had at least one type of platinum chemotherapy and an immunotherapy. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
AlicanteAges 18 years+ - NCT06790797Recruiting
Predicting immunotherapy success in chest cancers
This study is for people with lung or esophageal cancer who will receive immunotherapy (drugs that help your immune system fight cancer). The researchers want to find markers in your blood and tumor that can predict how well the treatment will work.
Suzhou, JiangsuAges 18–80 - NCT07459283RecruitingEarly Phase 1
Study of 177Lu-INN805 for advanced solid tumors
This trial tests a new treatment called 177Lu-INN805 for people with advanced solid tumors that have not responded to standard therapies. It aims to see if the drug is safe, where it goes in the body, and whether it can shrink tumors.
Wuxi, JiangsuAges 18–75 - NCT07365319RecruitingPhase 2/Phase 3
New drug combo for stage 4 lung cancer
This trial tests a new drug called EIK1001 combined with standard immunotherapy (pembrolizumab) and chemotherapy for people with stage 4 non-small cell lung cancer who have not been treated before. The goal is to see if adding EIK1001 helps shrink tumors more than the current standard treatment.
Daphne, AlabamaAges 18 years+ - NCT06692972Recruiting
How lung cancer tumors change after high-dose radiation
This study looks at how the main lung tumor shrinks or changes after a complete course of high-dose radiation in people with stage II or III lung cancer. It uses scans taken before and after treatment to track the results.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07325136RecruitingPhase 1/Phase 2
BMS-986525 for Relapsed Small Cell Lung Cancer
This study tests a new drug called BMS-986525, alone or with other treatments, for people with small cell lung cancer that has come back or not responded to treatment. It aims to find out if the drug is safe and tolerable.
Detroit, MichiganAges 18 years+ - NCT07306624RecruitingPhase 2
Nelmastobart plus docetaxel for advanced lung cancer
This trial tests a new drug, nelmastobart, combined with the chemotherapy docetaxel, for people with advanced non-small cell lung cancer that has a high level of a protein called BTN1A1. It is for patients who have already tried other treatments and are looking for a new option.
Gyeonggi-doAges 19 years+ - NCT07249372RecruitingPhase 2
DRP-104 for a specific type of advanced lung cancer
This trial tests a new drug, DRP-104, for people with advanced non-small cell lung cancer that has a change in the NFE2L2 or KEAP1 genes. It is for people whose cancer has gotten worse after standard treatments like chemotherapy and immunotherapy.
New York, New YorkAges 18 years+ - NCT07189455RecruitingPhase 3
Comparing ZG006 to chemotherapy for relapsed small cell lung cancer
This study compares a new drug called ZG006 against standard chemotherapy for people with small cell lung cancer that has come back after prior treatment. The goal is to see if ZG006 works better or has fewer side effects.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07174388Recruiting
Study comparing treatments for advanced lung cancer using medical records
This trial does not test a new drug. It looks at existing medical records to compare how well different treatments work for people with advanced non-small cell lung cancer. You may be eligible if your cancer is advanced and you are not in another clinical trial.
Monterey, CaliforniaAges 18 years+ - NCT07174583RecruitingPhase 1/Phase 2
Study of IDE849 for DLL3-positive cancers like SCLC
This trial tests a new drug called IDE849 for cancers that make a protein called DLL3, including small cell lung cancer and some neuroendocrine tumors. It is for people whose cancer has progressed after standard treatments, and may be given alone or combined with other drugs like durvalumab or IDE161.
Denver, ColoradoAges 18 years+ - NCT07133425RecruitingPhase 2
Study of a new immune drug for resistant lung cancer
This trial tests a new drug (SAR445877) for people with advanced non-small cell lung cancer whose cancer continued to grow despite immunotherapy. It aims to see if this treatment can help when other options have stopped working.
Houston, TexasAges 18 years+ - NCT07066813Recruiting
Lung cancer with air pockets: staging and treatment
This study looks at lung cancers that have air-filled spaces inside them. It explores how the stage of the cancer affects treatment outcomes. If you have this type of lung cancer and have had surgery, this trial may help doctors learn more about your condition.
Changsha, HunanAges Any age - NCT07027514RecruitingPhase 1
Combination treatment for advanced lung cancer
This study tests a new drug called tolododekin alfa combined with an approved immunotherapy drug for people with advanced non-small cell lung cancer. The goal is to see if this combination is safe and effective.
Coral Gables, FloridaAges 18 years+ - NCT07028489Recruiting
Studying a standard-care comparison group for advanced EGFR-mutant lung cancer
This trial collects information from people with a specific type of advanced lung cancer to create a comparison group. It helps researchers understand how well new treatments work without giving any experimental medicine.
Monterey, CaliforniaAges 18 years+ - NCT06902272RecruitingPhase 2
Blood test to predict chemo-immunotherapy response in lung cancer
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
Miami, FloridaAges 18 years+ - NCT06868485RecruitingPhase 2
Study of WSD0922-FU for advanced lung cancer with C797S mutation
This trial tests a new drug, WSD0922-FU, for people with advanced non-small cell lung cancer that has a specific genetic change called C797S. It is for those whose cancer has gotten worse after treatment with osimertinib.
Oxnard, CaliforniaAges 18 years+ - NCT06861543RecruitingPhase 1
TMT101 for advanced pancreatic or lung cancer
This trial tests a new drug called TMT101 for people with advanced pancreatic cancer or non-small cell lung cancer who have already tried other treatments. The goal is to see if TMT101 is safe and works against the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06759857Enrolling by invitationPhase 3
New drug vs. afatinib for EGFR-mutant lung cancer
This trial compares a new drug (FHND9041) to a standard targeted therapy (afatinib) for people with advanced lung cancer that has a specific EGFR mutation. It aims to see if the new drug works better or has fewer side effects.
BeijingAges 1.5 years+
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer?
- Yes. Clin2 currently lists 2,010 recruiting lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.